| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.57(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.23 - $9.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,011,778 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
775,593 |
1,206,168 |
1,357,304 |
2,009,275 |
| Total Sell Value |
$6,587,745 |
$9,420,070 |
$9,994,774 |
$10,729,161 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
18 |
37 |
60 |
105 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nea 12 Gp, Llc |
10% Owner |
– – • |
2015-06-05 |
4 |
B |
$10.70 |
$20,000,001 |
D/D |
1,869,159 |
7,488,893 |
2.45 |
- |
|
| Kolluri Krishna Kittu |
10% Owner |
– – • |
2015-06-05 |
4 |
B |
$10.70 |
$49,999,998 |
I/I |
4,672,897 |
1,401,869 |
1.5 |
- |
|
| Schultz Peter G |
Director |
– • – |
2015-06-05 |
4 |
B |
$10.70 |
$500,000 |
D/D |
46,729 |
907,429 |
2.39 |
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2015-05-04 |
4 |
AS |
$10.81 |
$98,232 |
D/D |
(9,083) |
596 |
|
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2015-05-04 |
4 |
OE |
$0.54 |
$4,905 |
D/D |
9,083 |
9,679 |
|
- |
|
| Cmea Ventures Vii (parallel) Lp |
10% Owner |
– – • |
2015-04-08 |
4 |
D |
$0.00 |
$0 |
I/I |
(10,000) |
70,990 |
|
- |
|
| Cmea Ventures Vii (parallel) Lp |
10% Owner |
– – • |
2015-04-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(390,000) |
2,768,716 |
|
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2015-04-06 |
4 |
AS |
$12.80 |
$98,331 |
D/D |
(7,681) |
596 |
|
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2015-04-06 |
4 |
OE |
$0.54 |
$4,148 |
D/D |
7,681 |
8,277 |
|
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2015-03-03 |
4 |
AS |
$15.60 |
$94,748 |
D/D |
(6,075) |
596 |
|
- |
|
| Kaufmann Mark |
Chief Financial Officer |
• – – |
2015-03-03 |
4 |
OE |
$0.54 |
$3,281 |
D/D |
6,075 |
6,671 |
|
- |
|
| Grammer Elizabeth A |
VP, General Counsel |
• – – |
2015-03-02 |
4 |
AS |
$15.81 |
$27,470 |
D/D |
(1,737) |
5,000 |
|
- |
|
| Jacobs Jeffrey W |
VP, Chemistry |
• – – |
2015-03-02 |
4 |
AS |
$15.81 |
$15,513 |
D/D |
(981) |
46,666 |
|
- |
|
| Jue George |
VP, Operations |
• – – |
2015-03-02 |
4 |
AS |
$15.88 |
$23,822 |
D/D |
(1,500) |
24,134 |
|
- |
|
| Jacobs Jeffrey W |
VP, Chemistry |
• – – |
2015-02-04 |
4 |
AS |
$16.07 |
$144,736 |
D/D |
(8,888) |
46,666 |
|
- |
|
| Jacobs Jeffrey W |
VP, Chemistry |
• – – |
2015-02-04 |
4 |
OE |
$1.08 |
$9,599 |
D/D |
8,888 |
55,554 |
|
- |
|
| Cmea Ventures Vii (parallel) Lp |
10% Owner |
– – • |
2015-01-30 |
4 |
S |
$27.37 |
$116,323 |
I/I |
(4,250) |
80,990 |
|
- |
|
| Cmea Ventures Vii (parallel) Lp |
10% Owner |
– – • |
2015-01-30 |
4 |
S |
$27.37 |
$4,536,578 |
D/D |
(165,750) |
3,158,716 |
|
- |
|
| Cmea Ventures Vii (parallel) Lp |
10% Owner |
– – • |
2015-01-08 |
4 |
S |
$24.25 |
$181,875 |
I/I |
(7,500) |
85,240 |
|
- |
|
| Cmea Ventures Vii (parallel) Lp |
10% Owner |
– – • |
2015-01-08 |
4 |
S |
$24.25 |
$7,093,125 |
D/D |
(292,500) |
3,324,466 |
|
- |
|
| Cmea Ventures Vii (parallel) Lp |
10% Owner |
– – • |
2014-12-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(10,000) |
92,740 |
|
- |
|
| Cmea Ventures Vii (parallel) Lp |
10% Owner |
– – • |
2014-12-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(390,000) |
3,616,966 |
|
- |
|
| Kolluri Krishna Kittu |
10% Owner |
– – • |
2014-12-29 |
4 |
S |
$20.09 |
$5,364 |
I/I |
(267) |
0 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2014-12-26 |
4 |
S |
$21.28 |
$41,961 |
I/I |
(1,972) |
0 |
|
- |
|
| Baskett Forest |
10% Owner |
– – • |
2014-12-26 |
4 |
S |
$21.28 |
$41,961 |
I/I |
(1,972) |
0 |
|
- |
|
538 Records found
|
|
Page 20 of 22 |
|
|
0.17 (2.57%) 
